Federation Des Caisses Desjardins Du Quebec Avidity Biosciences, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.9 Billion
- Q3 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 165 shares of RNA stock, worth $5,293. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165
Previous 165
-0.0%
Holding current value
$5,293
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
252Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$341 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$296 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$277 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$261 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$226 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.67B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...